Clinical Trial Update: Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether zoledronic acid can prevent bone mineral density loss in ART-naive HIV-positive individuals starting TDF-sparing antir…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Osteopenia

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: HIV Infected Individuals, Osteopenia | Phase 4 | Status: RECRUITING